Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6608 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2024-12-29 (pta-in-love.de)
Fumaderm: production will be discontinued -
Biogen is discontinuing production and distribution of Fumaderm initial and Fumaderm. Patients must be switched to alternatives.
Read more
2024-12-20 (apotheke-adhoc.de)
Out for Fumaderm |
Biogen is discontinuing production and distribution of Fumaderm initial and Fumaderm. Patients must be switched to alternatives.
Read more
2023-05-26 (beingpatient.com)
Shhhh! How Silencing Genes Could Treat Alzheimer’s | Being Patient
Biogen is testing a new type of drug in clinical trials that shuts off tau protein production before it becomes a problem.
Read more
2023-04-26 (endpts.com)
Following CRL, Form 483 reveals more quality issues at Alvotech’s production facility in Iceland
Another Form 483 for the Icelandic biosimilar manufacturer Alvotech’s manufacturing facility has shed more light on a recent complete response letter from the FDA that's stalling the company's potential new Humira competitor.
Read more
2021-05-21 (bostonglobe.com)
Biogen taps Ginkgo Bioworks to work on gene therapy manufacturing program
The companies’ goal is to make the production process more efficient.
Read more
2019-03-12 (genengnews.com)
Fujifilm Diosynth to Expand with $890M Purchase of Biogen’s Danish Biologics Manufacturing Site
Fujifilm has agreed to acquire Biogen’s large-scale biologics manufacturing site in Hillerød, Denmark, near Copenhagen for approximately $890 million cash, the companies said today, in a deal designed to strengthen the buyer’s ability to deliver large production volumes through “scale up.”
Read more
2010-02-15 (genengnews.com)
Trends in Monoclonal Antibody Production
Quality by design approach strives for greater process control and product quality.
Read more
2003-05-22 (pharmaceutical-technology.com)
Biogen Idec Pharmaceutical Production Facility - Pharmaceutical Technology
In March 2003 Biogen Idec began construction of its first production facility to be located outside of the USA. The...
Read more
(newsdeutschland.com)
Biogen plant near Solothurn ramps up: Breakthrough for the first Alzheimer's drug - is produced in Switzerland
The first therapy is there that slows the progression of the brain disease. With the proper approval in the USA, health insurance companies reimburse the costs there. • Economy • News Germany: 07.07.2023
Read more